Publication: Pentabromopseudilin: a myosin V inhibitor suppresses TGF-β activity by recruiting the type II TGF-β receptor to lysosomal degradation
Issued Date
2018-01-01
Resource Type
ISSN
14756374
14756366
14756366
Other identifier(s)
2-s2.0-85047248893
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Enzyme Inhibition and Medicinal Chemistry. Vol.33, No.1 (2018), 920-935
Suggested Citation
Wang Shih-Wei, Chung Chih-Ling, Yu Chen Kao, René Martin, Hans Joachim Knölker, Meng Shin Shiao, Chun Lin Chen Pentabromopseudilin: a myosin V inhibitor suppresses TGF-β activity by recruiting the type II TGF-β receptor to lysosomal degradation. Journal of Enzyme Inhibition and Medicinal Chemistry. Vol.33, No.1 (2018), 920-935. doi:10.1080/14756366.2018.1465416 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/47342
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pentabromopseudilin: a myosin V inhibitor suppresses TGF-β activity by recruiting the type II TGF-β receptor to lysosomal degradation
Abstract
© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Pentabromopseudilin (PBrP) is a marine antibiotic isolated from the marine bacteria Pseudomonas bromoutilis and Alteromonas luteoviolaceus. PBrP exhibits antimicrobial, anti-tumour, and phytotoxic activities. In mammalian cells, PBrP is known to act as a reversible and allosteric inhibitor of myosin Va (MyoVa). In this study, we report that PBrP is a potent inhibitor of transforming growth factor-β (TGF-β) activity. PBrP inhibits TGF-β-stimulated Smad2/3 phosphorylation, plasminogen activator inhibitor-1 (PAI-1) protein production and blocks TGF-β-induced epithelial–mesenchymal transition in epithelial cells. PBrP inhibits TGF-β signalling by reducing the cell-surface expression of type II TGF-β receptor (TβRII) and promotes receptor degradation. Gene silencing approaches suggest that MyoVa plays a crucial role in PBrP-induced TβRII turnover and the subsequent reduction of TGF-β signalling. Because, TGF-β signalling is crucial in the regulation of diverse pathophysiological processes such as tissue fibrosis and cancer development, PBrP should be further explored for its therapeutic role in treating fibrotic diseases and cancer.